The Calreticulin Exon 9 assay detects insertions or deletions that result in frameshift mutations, which alter the resulting protein's function
Lavender (EDTA), 4mL
Whole blood:
Lt blue Sodium citrate (NaCit)
Yellow ACD (A or B)
Bone marrow:
Lavender (EDTA), 4mL
Molecular Medicare billing request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Ambient (preferred)
Refrigerated (acceptable)
Polymerase Chain Reaction (PCR) + capillary electrophoresis
No mutation detected
These CALR mutations are seen in 67% to 88% of patients with essential thrombocythemia or primary myelofibrosis who lack JAK2 or MPL mutations (JAK2, MPL, and CALR mutations are mutually exclusive). CALR mutations are not limited to patients with myeloproliferative neoplasms as they can be seen infrequently in patients with myelodysplastic syndromes or mixed myelodysplastic/myeloproliferative syndromes. The Calreticulin Exon 9 Assay can be ordered as a reflex to a negative JAK2 V617F Mutation Detection. The reflex must be indicated on the request form or in the Excellian order. If ordered as a reflex, do not order the individual assay.
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.